pgo_normal: Probability to go to phase III for multiarm programs with...

In Sterniii3/drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning

Probability to go to phase III for multiarm programs with normally distributed outcomes

Description

Given our parameters this function calculates the probability to go to phase III after the second phase was conducted. The considered strategies are as follows:

• 1. Strategy: Only best promising treatment goes to phase III

Usage

pgo_normal(kappa, n2, Delta1, Delta2, strategy, case)

Arguments

kappa	threshold value for the go/no-go decision rule
n2	total sample size for phase II; must be an even number
Delta1	assumed true treatment effect for standardized difference in means
Delta2	assumed true treatment effect for standardized difference in means
strategy	choose Strategy: 1 ("only best promising"), 2 ("all promising")
case	different cases: 1 ("nogo"), 21 (treatment 1 is promising, treatment 2 is not), 22 (treatment 2 is promising, treatment 1 is not), 31 (both treatments are promising, treatment 1 is better), 32 (both treatments are promising, treatment 2 is better)

Value

The function pgo_normal() returns the probability to go to phase III for multiarm programs with normally distributed outcomes

Examples

res <- pgo_normal(kappa = 0.1, n2 = 50, Delta1 = 0.375, Delta2 = 0.625, strategy = 2, case = 31)

Sterniii3/drugdevelopR documentation built on Jan. 26, 2024, 6:17 a.m.